Limitations
This analysis considered only a limited number of demographic and clinical factors so clinical characteristics of subjects predicting a therapeutic response to Benralizumab could not be adequately assessed. Other limitations are the small number of subjects enrolled and the single blind pilot study design. Although this was a small study, there was an adequate power to predict a clinical significance in the UAS7 primary endpoint. With respect to the study design, it should be emphasized that pilot studies represent a fundamental phase of the clinical research process and are essential for determining the feasibility of pursing a larger clinical trial 50which is supported by the results of this study.